Regeneron Pharmaceuticals, Inc.
Regeneron Provides Q4 2025 Corporate Update: Financial Outlook and Charges
Summary
Regeneron Pharmaceuticals, Inc. provided a corporate update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The update included preliminary financial information for the fourth quarter and full year 2025, which is subject to the company's financial statement closing procedures. The company expects an acquired in-process research and development (IPR&D) charge of approximately $19 million on a pre-tax basis, which will negatively impact GAAP and non-GAAP net income per diluted share by approximately $0.14 for Q4 2025. Additionally, Regeneron committed to a matching program for donations to Good Days, recording a corresponding charge for its matching contribution recorded to selling, general, and administrative expenses of approximately $60 million. The update did not include finalized results and there can be no assurance that actual results will not differ from the preliminary estimates.
Profitelligence Alerts
Get alerts for REGN
Be first to know when Regeneron Pharmaceuticals, Inc. files with the SEC.
Filing Categories
Advertisement
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Official SEC Documents
Advertisement